These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10312332)

  • 1. Buprenorphine: a cost-effective alternative to Schedule II analgesics for moderate to severe pain relief.
    Rosenthal MH; Bayait F
    Hosp Formul; 1988 Jan; 23(1):57-60, 62, 71. PubMed ID: 10312332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of drug distribution costs for controlled versus noncontrolled oral analgesics.
    Reynolds RC; Ploetz P; Thielke TS
    Am J Hosp Pharm; 1984 Aug; 41(8):1558-63. PubMed ID: 6475974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost-avoidance with oral extended-release morphine sulfate tablets versus morphine sulfate solution.
    Goughnour BR; Arkinstall WW
    Am J Hosp Pharm; 1991 Jan; 48(1):101-4. PubMed ID: 2000864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital labor cost savings in dispensing analgesics: controlled versus noncontrolled.
    Townsend RJ; Spartz ME; Fahrenbruch RW; Salbenblatt MF; Parfet DR
    Hosp Formul; 1983 Jul; 18(7):716-20. PubMed ID: 10260989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microcost analysis of inpatient dispensing and administration of oral solids.
    Hatoum HT
    Am J Hosp Pharm; 1990 Apr; 47(4):800-5. PubMed ID: 2321657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential for nonnarcotic analgesics to save personnel costs associated with controlling injectable morphine and meperidine.
    Koffer H; Hildebrand JR; Connell ML
    Am J Hosp Pharm; 1990 May; 47(5):1084-8. PubMed ID: 2337099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of a satellite pharmacy.
    Kelly WN; Meyer JD; Flatley CJ
    Am J Hosp Pharm; 1986 Aug; 43(8):1927-30. PubMed ID: 3092647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic comparison of Tubex injection systems with traditional ampuls and vials.
    Miller DE; Grainger WL; Woolard D; Timko JR; Adler DC
    Hosp Pharm; 1985 Aug; 20(8):584-91, 595. PubMed ID: 10272398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining drug dispensing costs for use in cost-accounting systems.
    Thielke TS; Charlson JT; Heckethorn D
    Am J Hosp Pharm; 1988 Apr; 45(4):844-7. PubMed ID: 3376969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication cart-filling time, accuracy, and cost with an automated dispensing system.
    Klein EG; Santora JA; Pascale PM; Kitrenos JG
    Am J Hosp Pharm; 1994 May; 51(9):1193-6. PubMed ID: 8042638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost comparison of intravenous cimetidine delivery systems.
    Jackson CW; Caldwell RD; Arford PD
    Hosp Pharm; 1990 Dec; 25(12):1085-9. PubMed ID: 10108250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost considerations of analgesic therapy: an analysis of the effects of dosing frequency and route of administration.
    Goughnour BR
    Postgrad Med J; 1991; 67 Suppl 2():S87-91. PubMed ID: 1758824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine with bupivacaine for intraoral nerve blocks to provide postoperative analgesia in outpatients after minor oral surgery.
    Modi M; Rastogi S; Kumar A
    J Oral Maxillofac Surg; 2009 Dec; 67(12):2571-6. PubMed ID: 19925973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-utility and cost-effectiveness analysis of an acute pain service.
    Stadler M; Schlander M; Braeckman M; Nguyen T; Boogaerts JG
    J Clin Anesth; 2004 May; 16(3):159-67. PubMed ID: 15217653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.